You are on page 1of 2

Home Page

Bextra -- Valdecoxib
Pesticides
Foods
Antioxidants Supplements Life Emotions Disease Drugs and Solvents Fuels Color Materials
Insecticides
Today is Saturday, March 2, 2019

Home > Drugs> Bextra

The Bextra --
(Valdecoxib)
Molecule..

Bextra 3D
structure using
Jmol

Valdecoxib --Bextra

Bextra Structure

CHEMICAL FORMULA

C17H14F3N3O2S

Valdecoxib is a prescription drug used in the treatment of osteoarthritis,


rheumatoid arthritis, and painful menstruation and menstrual symptoms. It is
classified as a nonsteroidal anti-inflammatory drug, or NSAID, and should
not be taken by anyone allergic to these types of medications.

Valdecoxib was manufactured and marketed under the brand name Bextra by
G. D. Searle & Company. It was approved by the United States Food and
Drug Administration on November 20, 2001[1], and was available by
prescription in tablet form until 2005, when it was removed from the market
due to concerns about possible increased risk of heart attack and stroke.

Uses
Since its registration, Bextra was prescribed for pain associated with arthritis,
menstrual discomfort, and other ailments.

Side-effects and withdrawal

On April 7, 2005, Pfizer withdrew Bextra from the U.S. market on


recommendation by the FDA, citing an increased risk of heart attack and
stroke and also the risk of a serious, sometimes fatal, skin reaction. This was a
result of recent attention to prescription NSAIDs, such as Merck's Vioxx.
Other reported side-effects were angina and Stevens-Johnson syndrome.

Pfizer first acknowledged cardiovascular risks associated with Bextra in


October of 2004. The American Heart Association soon after was presented
with a report indicating patients using Bextra while recovering from heart
surgery were 2.19 times more likely to suffer a stroke or heart attack than
those taking placebos.

Recently in a large study published in JAMA 2006, valdecoxib appears less


adverse for renal (kidney) disease and heart arrhythmia compared to Vioxx,
however elevated renal risks were slightly suggested. [2]

References

1. Thomson Micromedex. "Valdecoxib. U.S. FDA Drug Approval." Last


accessed June 8, 2007.
2. "Adverse Effects of Cyclooxygenase-2 Inhibitors on Renal and
Arrhythmia Events: Meta-Analysis of Randomized Trials", (JAMA
2006, by Zhang JJ, Ding EL, Song Y.).

External links

FDA Alert on Bextra withdrawal

Some or all of this text has been obtained from Wikipedia, the free encyclopedia. All text is
available under the terms of the GNU Free Documentation License (see Copyrights for details).
Disclaimers. Wikipedia is powered by MediaWiki, an open source wiki engine.

Questions or Comments?

World of Molecules Home Page

You might also like